CARL

• 2026-05-05 share offering or dilution eventrecentOpen filing ↗
  “…Bank Credit Facility In December 2022, the Company entered into a loan and security agreement with Signature Bank, which was…”
  +1 more passage from the same document

  • “…(the “Customers Loan Agreement”). Under various amendments to the Customers Loan Agreement, the Company issued the lender a…”
• 2026-05-05 capital return (buybacks/dividends)recentOpen filing ↗
  “…a “Change in Control” or “Corporate Transaction,” as defined in the respective plans. The 2019 Plan allows for the exercise of…”
  +1 more passage from the same document

  • “…outstanding shares of convertible preferred stock were converted into 15,245,731 shares of common stock. 8. Net Loss Per Share Basic…”
• 2026-05-05 reverse splitrecentOpen filing ↗
  “…Technology Platform for cervical fusion surgeries. Also in December 2025, the Company received FDA 510(k) clearance for accompanying…”
  +1 more passage from the same document

  • “…Company received FDA 510(k) clearance for accompanying personalized cervical plating solutions. In February 2026, the Company…”
• 2026-02-25 share offering or dilution eventrecentOpen filing ↗
  “…of the Customers Loan Agreement. Interest Income Interest income is attributable to bank interest on our cash and cash equivalents…”
  +1 more passage from the same document

  • “…, the expiration date for the Series B Warrant was extended to December 30, 2034 . The modification of the Series B…”
• 2026-02-25 capital return (buybacks/dividends)recentOpen filing ↗
  “…a “Change in Control” or “Corporate Transaction,” as defined in the respective plans. The 2019 Plan allows for the exercise of…”
  +1 more passage from the same document

  • “…respect of such shares if all amounts payable on or with respect to such shares were paid in full. F- 24 8. Net Loss Per Share Basic…”
• 2026-02-25 reverse splitrecentOpen filing ↗
  “…launch of aprevo Technology Platform for cervical fusion surgeries. Also in December 2025, the Company received FDA 510(k) clearance…”
  +1 more passage from the same document

  • “…December 2025, the Company received FDA 510(k) clearance for accompanying personalized cervical plating solutions. We expect to more…”

Recorded SEC filings in plain language — not advice or a prediction.